Botox, Dysport, Xeomin not interchangeable

June 7, 2016

botoxBotox (onabotulinumtoxinA, Allergan), Dysport (abobotulinumtoxinA, Galderma) and Xeomin (incobotulinumtoxinA, Merz) do not have equivalent strain reduction, according to a study of glabellar line treatments. The results, researchers conclude, confirm non-interchangeability of these neurotoxins.
Researchers treated 73 treatment-naive females randomized to 20 units of Botox, 60 units of Dysport or 20 units of Xeomin in the glabella. They imaged patients 4, 14 and 90 days post injection and noted change in average dynamic glabella strain.
The researchers found that at day 4 the Botox group had a 42.1% strain reduction, vs. a 39.4% reduction in the Dysport group and 19.8% reduction in the Xeomin group. By day 14, there was a 66.1% strain reduction in the Botox patients; a 51.4% strain reduction in the Dysport group; and a 42.8% strain reduction among those receiving Xeomin. At day 90, the Botox group had a 43.5% strain reduction, vs. a 38.4% strain reduction among those receiving Dysport and a 25.3% strain reduction in the Xeomin group.
 
 
Register Today!  How to Successfully Open a Medical Spa–Northwest: September 19-20, 2016
How to Successfully Open a Medical Spa–Texas: November 6-7, 2016
Southwest Medical Spa Regulatory Workshop: December 5, 2016

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Cold Laser Therapy: The Science and Uses for Med Spas
    • Compounded Tirzepatide, NAD+ Injections Recalled Nationwide Over Sterility Concerns
    • Meliora Consulting Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations